Compass Therapeutics (CMPX)
Develops oncology antibody candidates for tumor microenvironment biology.
$1.16
vs last close−0.08 (−6.85%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 91.21% | 164.25M shares | |
|---|---|---|---|
| 222 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 4.29% | 7.72M shares | |
| 4 holders · as of Apr 30, 2026 | |||
| Other | ≈ 4.50% | 8.12M shares | |
| remainder | |||
180.09M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
222 holders · 164.25M shares · 66 new positions · 151 increased · 45 reduced · 52 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Tang Capital Management LLC | 17.99M | 9.99% | +1.20M | Aug 14, 2026 |
| Orbimed Advisors LLC | 15.22M | 8.45% | 0 | Aug 14, 2026 |
| Suvretta Capital Management, LLC | 14.10M | 7.83% | −206.2K | Aug 14, 2026 |
| BlackRock, Inc. | 11.28M | 6.26% | +1.78M | Aug 7, 2026 |
| State Street Corp | 9.95M | 5.53% | +3.26M | Aug 7, 2026 |
| Enavate Sciences GP, LLC | 7.79M | 4.32% | 0 | Aug 14, 2026 |
| Vivo Capital, LLC | 7.76M | 4.31% | −1.79M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 6.12M | 3.40% | +81.6K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Tang Capital Management, LLC | 9.99% | 17.18M | 13G | Nov 14, 2025 |
| RTW Investments, LP | 9.90% | 9.47M | 13G | Aug 14, 2025 |
| Orbimed Advisors LLCincl. Orbimed Capital GP V LLC | 8.90% | 15.22M | 13D | Aug 15, 2025 |
| Suvretta Capital Management, LLC | 8.20% | 14.10M | 13G | Aug 21, 2025 |
| State Street Corporation | 5.50% | 9.95M | 13G | Aug 7, 2026 |
| BlackRock, Inc. | 5.20% | 9.27M | 13G | Jan 21, 2026 |
| Vivo Opportunity Fund Holdings, L.P. | 5.10% | 9.00M | 13G | Nov 14, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Apr 29, 2026 | Jonathan Andermanofficer: General Counsel | Purchase | 25,000 | $1.89 | 196,000 |
| Apr 29, 2026 | Neil Lernerofficer: Chief Accounting Officer | Purchase | 15,000 | $1.89 | 397,500 |
House and Senate disclosures
Not reported.